FDA Seeks More Info On Bristol, AstraZeneca Diabetes Drug
The U.S. Food and Drug Administration on Thursday handed back Bristol-Myers Squibb Co. and AstraZeneca PLC's new drug application for Type 2 diabetes treatment dapagliflozin, asking for additional clinical trial data...To view the full article, register now.
Already a subscriber? Click here to view full article